Landscape Capital Management L.L.C. Has $215,000 Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

Landscape Capital Management L.L.C. trimmed its stake in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) by 87.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 52,085 shares of the company’s stock after selling 372,640 shares during the quarter. Landscape Capital Management L.L.C. owned 0.07% of Trevi Therapeutics worth $215,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. Bank of New York Mellon Corp boosted its stake in Trevi Therapeutics by 2.1% in the 4th quarter. Bank of New York Mellon Corp now owns 140,219 shares of the company’s stock valued at $578,000 after buying an additional 2,935 shares in the last quarter. SG Americas Securities LLC grew its holdings in shares of Trevi Therapeutics by 14.5% in the 4th quarter. SG Americas Securities LLC now owns 26,792 shares of the company’s stock worth $110,000 after purchasing an additional 3,387 shares during the last quarter. BNP Paribas Financial Markets increased its position in shares of Trevi Therapeutics by 130.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock worth $40,000 after purchasing an additional 6,764 shares in the last quarter. Raymond James Financial Inc. bought a new position in Trevi Therapeutics during the 4th quarter valued at about $49,000. Finally, China Universal Asset Management Co. Ltd. acquired a new position in Trevi Therapeutics in the fourth quarter valued at about $67,000. 95.76% of the stock is currently owned by institutional investors.

Trevi Therapeutics Trading Down 8.3 %

Trevi Therapeutics stock opened at $5.30 on Wednesday. Trevi Therapeutics, Inc. has a 1 year low of $2.30 and a 1 year high of $7.39. The company’s 50-day moving average is $5.19 and its two-hundred day moving average is $4.02. The company has a market cap of $512.41 million, a PE ratio of -12.05 and a beta of 0.41.

Trevi Therapeutics (NASDAQ:TRVI) last announced its quarterly earnings data on Tuesday, March 18th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.01. Research analysts forecast that Trevi Therapeutics, Inc. will post -0.49 EPS for the current year.

Insider Buying and Selling

In other news, CEO Jennifer L. Good sold 5,263 shares of the company’s stock in a transaction dated Friday, March 21st. The stock was sold at an average price of $6.58, for a total value of $34,630.54. Following the completion of the sale, the chief executive officer now directly owns 213,313 shares of the company’s stock, valued at $1,403,599.54. This represents a 2.41 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Farrell Simon sold 81,313 shares of Trevi Therapeutics stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $6.75, for a total transaction of $548,862.75. Following the transaction, the insider now directly owns 76,900 shares in the company, valued at $519,075. The trade was a 51.39 % decrease in their position. The disclosure for this sale can be found here. 24.37% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. Oppenheimer lifted their target price on shares of Trevi Therapeutics from $12.00 to $20.00 and gave the company an “outperform” rating in a research note on Tuesday, March 11th. HC Wainwright reiterated a “buy” rating and issued a $12.50 price objective on shares of Trevi Therapeutics in a research report on Wednesday, March 19th. Raymond James upgraded Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and increased their target price for the stock from $9.00 to $29.00 in a report on Monday, March 10th. D. Boral Capital reaffirmed a “buy” rating and issued a $21.00 price target on shares of Trevi Therapeutics in a report on Wednesday, March 19th. Finally, Needham & Company LLC reissued a “buy” rating and set a $24.00 price objective on shares of Trevi Therapeutics in a report on Tuesday. Seven investment analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $17.56.

Trevi Therapeutics Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.